Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.67 |
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.65 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.59 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.59 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10264586 | 0.97 | L3MBTL3 (0.69) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL3923604 | 0.89 | HRH3 (0.64) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL10264005 | 0.89 | L3MBTL3 (0.77) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL17888405 | 0.88 | ALDH1A1 (0.64) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL12156450 | 0.87 | L3MBTL3 (0.78) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3926615 | 0.87 | HRH3 (0.68) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL3917908 | 0.87 | HRH3 (0.61) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL17888363 | 0.86 | L3MBTL3 (0.69) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL3920090 | 0.85 | HRH3 (0.60) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL3917660 | 0.84 | KDM4E (0.68) | HRH3L3MBTL3L3MBTL1MBTD1TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101511807-A | Substituted benzamide modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-19 | — | — | CN | claimed |
| EP-2038269-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-25 | — | — | EP | claimed |
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | claimed |
| WO-2008002816-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | claimed |
| WO-2015069110-A1 | MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS | AAPA B.V. (NL) | 2015-05-14 | — | — | WO | disclosed |
| CN-101511807-A | Substituted benzamide modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-19 | — | — | CN | disclosed |
| EP-2038269-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-25 | — | — | EP | disclosed |
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| WO-2008002816-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008002816-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045507-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885L3MBTL3 2202/4885L3MBTL1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.